Transforming growth factor-beta is involved in the pathogenesis of dialysis-related amyloidosis.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Kidney International

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1523-1755.2000.t01-1-00892.xPMID 10652049
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transforming growth factor-beta 1 hyperexpression in African American end-stage renal disease patients.

  1998cited by this paper
• Alterations of synovial tissue and their potential role in the deposition of beta2-microglobulin-associated amyloid.

  1998cited by this paper
• Interaction between beta 2-microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis.

  1997cited by this paper
• Monocyte/macrophage response to beta 2-microglobulin modified with advanced glycation end products.

  1996cited by this paper
• Monocyte production of transforming growth factor beta in long-term hemodialysis: modulation by hemodialysis membranes.

  1996cited by this paper
• The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis.

  1996cited by this paper
• Immunohistochemical detection of advanced glycation end products in dialysis-related amyloidosis.

  1995cited by this paper
• Protection of transforming growth factor-beta 1 activity by heparin and fucoidan.

  1994cited by this paper
• Transforming growth factor-beta 1 mediates mast cell chemotaxis.

  1994cited by this paper
• Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1.

  1994cited by this paper
• Transforming growth factor-beta mediates IL-1-dependent induction of IL-1 receptor antagonist.

  1993cited by this paper
• Kinetics of technetium-labeled heparin in hemodialyzed patients.

  1993cited by this paper
• Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta).

  1993cited by this paper
• beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis.

  1993cited by this paper
• Cloning of a TGF beta type I receptor that forms a heteromeric complex with the TGF beta type II receptor.

  1993cited by this paper
• Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin-10.

  1992cited by this paper
• Transforming growth factor beta (TGF-beta) in inflammation: a cause and a cure.

  1992cited by this paper
• Dialysis-related amyloidosis.

  1992cited by this paper
• Type I transforming growth factor-beta receptors on neutrophils mediate chemotaxis to transforming growth factor-beta.

  1991cited by this paper
• Beta-2-microglobulin amyloidosis and renal bone disease.

  1991cited by this paper
• Differential susceptibility of activated macrophage cytotoxic effector reactions to the suppressive effects of transforming growth factor-beta 1.

  1991cited by this paper
• Production of IL-1 receptor antagonist by human in vitro-derived macrophages. Effects of lipopolysaccharide and granulocyte-macrophage colony-stimulating factor.

  1991cited by this paper
• Transforming growth factor beta 1, a potent chemoattractant for human neutrophils, bypasses classic signal-transduction pathways.

  1991cited by this paper
• Induction of the interleukin 1 receptor antagonist protein by transforming growth factor‐β

  1991cited by this paper
• Effects of acetate dialysate on transforming growth factor beta 1, interleukin, and beta 2-microglobulin plasma levels.

  1991cited by this paper
• Macrophage deactivating factor and transforming growth factors-beta 1 -beta 2 and -beta 3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-gamma.

  1990cited by this paper
• The transforming growth factor-beta family.

  1990cited by this paper
• TGF-beta regulates production of growth factors and TGF-beta by human peripheral blood monocytes.

  1990cited by this paper
• The effects of differentiating agents on IL-1 beta production in cultured human monocytes.

  1990cited by this paper
• Transforming growth factor beta is a potent inhibitor of interleukin 1 (IL-1) receptor expression: proposed mechanism of inhibition of IL-1 action

  1990cited by this paper
• Modulation of cytokine production by transforming growth factor-beta.

  1989cited by this paper
• Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha 2- macroglobulin inactive complex

  1989cited by this paper
• Inflammatory and immunomodulatory roles of TGF-beta.

  1989cited by this paper
• Transforming growth factor-beta: possible roles in carcinogenesis.

  1988cited by this paper
• Transforming growth factor-beta (TGF beta) is chemotactic for human monocytes and induces their expression of angiogenic activity.

  1988cited by this paper
• Deactivation of macrophages by transforming growth factor-beta.

  1988cited by this paper
• Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling.

  1988cited by this paper
• Transforming growth factor type beta induces monocyte chemotaxis and growth factor production.

  1987cited by this paper
• Inhibition of cytokine production by cyclosporin A and transforming growth factor beta

  1987cited by this paper
• Interleukin-1 production and antigen presentation by normal human peritoneal macrophages.

  1986cited by this paper
• High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules.

  1985cited by this paper
• A new form of amyloid protein associated with chronic hemodialysis was identified as beta 2-microglobulin.

  1985cited by this paper
• Normal human alveolar macrophages obtained by bronchoalveolar lavage have a limited capacity to release interleukin-1.

  1984cited by this paper
• The isolation and purification of human peripheral blood monocytes in cell suspension.

  1980cited by this paper

• Exploring the Molecular Pathology of Iatrogenic Amyloidosis

  2024cites this paper
• Beta-2 Microglobulin Amyloidosis: Past, Present, and Future.

  2020cites this paper
• Ghent University

  2020cites this paper
• Blood lead level: an overlooked risk of carpal tunnel syndrome in hemodialysis patients

  2019cites this paper
• Association Between Environmental Particulate Matter and Carpal Tunnel Syndrome in Patients Undergoing Hemodialysis

  2017cites this paper
• Significance of the decreased risk of dialysis-related amyloidosis now proven by results from Japanese nationwide surveys in 1998 and 2010.

  2016cites this paper
• Uremia-related oxidative stress in leukocytes is not triggered by β2-microglobulin.

  2013cites this paper
• Cellular signalling of the receptor for advanced glycation end products (RAGE).

  2013cites this paper
• Microglia in neurodegenerative disease

  2010cites this paper
• Amiloidosis, a mysterious disease, still underestimated

  2008cites this paper
• Bone marrow progenitors from animals with chronic renal failure lack capacity of in vitro proliferation.

  2008cites this paper
• Enoxaparin but not unfractionated heparin causes a dose-dependent increase in plasma TGF-beta 1 during haemodialysis: a cross-over study.

  2007cites this paper
• Reviews: Uremic Toxins: A New Focus on an Old Subject

  2005cites this paper
• Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis.

  2004cites this paper
• Single-chain antibody fragment-based adsorbent for the extracorporeal removal of beta2-microglobulin.

  2004cites this paper
• Sorbents in Acute Renal Failure and End-Stage Renal Disease: Middle Molecule and Cytokine Removal

  2004cites this paper
• Histological analysis of the ligamentum flavum of patients with dialysis-related spondyloarthropathy

  2004cites this paper
• Beta-2 microglobulin in ESRD: an in-depth review.

  2003cites this paper
• Cellular uptake of beta2M and AGE-beta2M in synovial fibroblasts and macrophages.

  2003cites this paper
• Signal transduction of beta2m-induced expression of VCAM-1 and COX-2 in synovial fibroblasts.

  2002cites this paper
• Hemodialysis membranes: interleukins, biocompatibility, and middle molecules.

  2002cites this paper
• Beta(2)-microglobulin amyloidosis: effects of ultrapure dialysate and type of dialyzer membrane.

  2002cites this paper
• Cellular uptake of b 2 M and AGE- b 2 M in synovial fibroblasts and macrophages

  2002cites this paper
• AGE-b2M in synovial fibroblasts and macrophages

  2002cites this paper
• Beta 2-microglobulin amyloidosis: role of monocytes/macrophages

  2002cites this paper
• Haemodialysis, atherosclerosis and inflammation-identifying molecular mechanisms of chronic vascular disease in ESDR patients.

  2002cites this paper
• Pathogenesis of β2‐Microglobulin Amyloidosis: Role of Monocytes/Macrophages

  2001cites this paper
• Dialysis‐Related Amyloidosis: Pathogenesis Focusing on AGE Modification

  2001cites this paper
• Pathological Aspects of β2‐Microglobulin Amyloidosis

  2001cites this paper
• beta2-microglobulin-derived amyloidosis: an update.

  2001cites this paper
• The Role of the Synovium and Cartilage in the Pathogenesis of β2‐Microglobulin Amyloidosis

  2001cites this paper
• beta(2)-Microglobulin increases the expression of vascular cell adhesion molecule on human synovial fibroblasts.

  2001cites this paper